Home Featured US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

0
US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says


Source: Streetwise Reports  (11/11/22)

Aldeyra Therapeutics is undervalued because of its late-stage drug candidates as well as major near-term catalysts. According to analysts, it deserves a Buy-to-Outperform rating. Potential investors should consider Aldeyra Therapeutics.

One new drug candidate is on the verge for approval in the U.S., and another one is close behind. Aldeyra Therapeutics Inc. (ALDX:NASDAQ). Is Experts say the market is currently undervalued and offers an attractive, but highly-desked opportunity for investment.

The Massachusetts-based company develops treatments for immune-mediated disorders. These treatments regulate whole immunological systems and not alter one protein. The biopharma is currently working on three therapeutic candidates.

A trio of potential new therapies

1) Reproxalap: This RASP, or reactive aldehyde species, inhibiting 0.25% ophthalmic solution for dry eye disease is Aldeyra’s lead drug candidate, for which the company is on schedule to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) by year-end.

Approval “could lead to a meaningful lift for the shares,” purported Oppenheimer Analyst Justin…



Continue reading…